Castle Creek Biosciences

Exton, United States Founded: 2018 • Age: 8 yrs
Gene therapy platform for rare disease treatments is developed.
Annual revenue - Latest available
Total funding $192.8M 4 rounds
Employees 41 Tracked headcount
Investors 4 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Castle Creek Biosciences

Castle Creek Biosciences is a company based in Exton (United States) founded in 2018. Castle Creek Biosciences has raised $192.8 million across 4 funding rounds from investors including Fidelity Investments, Paragon Biosciences and Horizon Tech Finance. The company has 41 employees as of December 31, 2022. Castle Creek Biosciences operates in a competitive market with competitors including Ironwood Pharma, Amryt Pharma, Castle Creek Pharma, VeraDermics and Lipum, among others.

  • Headquarter Exton, United States
  • Employees 41 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Castle Creek Biosciences, Llc
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $192.8 M (USD)

    in 4 rounds

  • Latest Funding Round
    $112.8 M (USD), Series D

    Jan 18, 2022

  • Investors
  • Employee Count
    41

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Castle Creek Biosciences

Headcount 10-50
Employee Profiles 11
Board Members and Advisors 1
Employee Profiles
People
Matthew Gantz
Chairman & CEO
People
Mayo Pujols
Chief Operating Officer
People
Savita Mehra
AVP, Quality Assurance
People
Matthew Crabtree
Senior Director, Finance

Unlock access to complete

Funding Insights of Castle Creek Biosciences

Castle Creek Biosciences has successfully raised a total of $192.8M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $112.8 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Castle Creek Biosciences

Castle Creek Biosciences has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paragon Biosciences and Horizon Tech Finance.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity firm
Locked Locked Locked
Structured debt is provided to life sciences and technology firms.
Locked Locked Locked
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
Locked Locked Locked
Premium access

Investor details for Castle Creek Biosciences

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Castle Creek Biosciences

Investments
Premium access

Investment portfolio details for Castle Creek Biosciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Castle Creek Biosciences

Premium access

Detailed financials for Castle Creek Biosciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Castle Creek Biosciences Comparisons

Castle Creek Biosciences Primary company
Description
Gene therapy platform for rare disease treatments is develop...
Location
Exton, United States
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
41
As of 2022
Premium access

Peer comparison for Castle Creek Biosciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Castle Creek Biosciences

Castle Creek Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Amryt Pharma, Castle Creek Pharma, VeraDermics and Lipum, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
Locked Locked Locked
Therapeutics for rare dermatological and orphan diseases are developed.
Locked Locked Locked
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
Locked Locked Locked
Drug-delivery platforms for pediatric wart treatments are developed.
Locked Locked Locked
Developer of antibody to treat juvenile idiopathic arthritis
Locked Locked Locked
Medicines for chronic diseases in children are developed and provided.
Premium access

Detailed competitors of Castle Creek Biosciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Castle Creek Biosciences

Premium access

Complete news archive for Castle Creek Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Castle Creek Biosciences

Castle Creek Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Castle Creek Biosciences is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.

Castle Creek Biosciences is a funded company, having raised a total of $192.8M across 4 funding rounds to date.

As of Dec 31, 2022, the latest employee count at Castle Creek Biosciences is 41.

Castle Creek Biosciences was founded in 2018 and is headquartered in Exton, United States. A gene therapy platform based on autologous fibroblasts derived from patient skin cells is offered for rare skin and connective tissue disorders, including epidermolysis bullosa and localized scleroderma. Clinical development includes FCX-007 in phase 3 trials, with FCX-013 and CCP-020 in phase 2. Operations focus on dermatology and related rare disease areas.

Castle Creek Biosciences's top competitors include Ironwood Pharma, VeraDermics and Amryt Pharma.

Castle Creek Biosciences has 4 investors. Key investors include Fidelity Investments, Paragon Biosciences, Horizon Tech Finance, and Valor Equity Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available